Wan J, Imaoka S, Chow T, Hiroi T, Yabusaki Y, Funae Y
Laboratory of Chemistry, Osaka City University Medical School, Japan.
Arch Biochem Biophys. 1997 Dec 15;348(2):383-90. doi: 10.1006/abbi.1997.0402.
We cloned four cDNAs belonging to the CYP2D subfamily to express these enzymes in yeast cells and to compare their catalytic activities simultaneously. Three are believed to be alleles of CYP2D1, 2D2, and 2D3, respectively, based on high nucleotide sequence similarity, while CYP2D4 had both sequences of CYP2D4 and CYP2D18. Expression plasmids carrying CYP2D cDNAs were transformed into Saccharomyces cerevisiae. Typical P450 CO-difference spectra with absorbance maximum at 448 nm were recorded with microsomal preparations from the yeast cells expressing the four CYP2D forms. A catalytic study of these CYP2D forms was done with debrisoquine, bufuralol, and lidocaine. CYP2D2 had the highest debrisoquine 4-hydroxylation (2.2 nmol/min/nmol P450) activity, similar to that (2.2 nmol/min/nmol) of human CYP2D6 expressed in yeast cells. CYP2D3 had high lidocaine N-deethylation (43 nmol/min/nmol P450) activity, and both CYP2D3 and 2D2 exhibited high lidocaine 3-hydroxylation (2.4 and 1.6 nmol/min/nmol P450, respectively) activity. Bufuralol 1'-hydroxylation catalytic capabilities were comparable among the four isoforms. The activity of CYP2D1 was relatively low toward the three substrates (debrisoquine, 0.091; bufuralol, 1.5; lidocaine 3-hydroxylation, 0.019; lidocaine N-deethylation, 2.8 nmol/min/nmol P450). These findings indicate that debrisoquine, a typical substrate for CYP2D forms, was mainly metabolized by CYP2D2 but not CYP2D1 in rat liver and that the CYP2D forms have different substrate specificity.
我们克隆了属于CYP2D亚家族的四个cDNA,以便在酵母细胞中表达这些酶并同时比较它们的催化活性。基于高核苷酸序列相似性,其中三个分别被认为是CYP2D1、2D2和2D3的等位基因,而CYP2D4同时具有CYP2D4和CYP2D18的序列。携带CYP2D cDNA的表达质粒被转化到酿酒酵母中。用表达四种CYP2D形式的酵母细胞的微粒体制剂记录了典型的P450 CO-差光谱,其在448 nm处有最大吸光度。用异喹胍、丁呋洛尔和利多卡因对这些CYP2D形式进行了催化研究。CYP2D2具有最高的异喹胍4-羟化(2.2 nmol/分钟/纳摩尔P450)活性,与在酵母细胞中表达的人CYP2D6的活性(2.2 nmol/分钟/纳摩尔)相似。CYP2D3具有高的利多卡因N-脱乙基(43 nmol/分钟/纳摩尔P450)活性,并且CYP2D3和2D2都表现出高的利多卡因3-羟化(分别为2.4和1.6 nmol/分钟/纳摩尔P450)活性。四种同工型之间丁呋洛尔1'-羟化的催化能力相当。CYP2D1对三种底物(异喹胍,0.091;丁呋洛尔,1.5;利多卡因3-羟化,0.019;利多卡因N-脱乙基,2.8 nmol/分钟/纳摩尔P450)的活性相对较低。这些发现表明,异喹胍作为CYP2D形式的典型底物,在大鼠肝脏中主要由CYP2D2而非CYP2D1代谢,并且CYP2D形式具有不同的底物特异性。